Venture&Growth Archives - Page 6 of 59 - Gilde Healthcare

Menu
Menu
Home

Neuigkeiten & Einblicke
Venture&Growth

Gilde Healthcare portfolio company SpliceBio Announces U.S. FDA IND Clearance of SB-007

SB-007 is the only IND-cleared, clinical-stage therapeutic addressing the root cause of Stargardt disease with the potential to treat all patients across all ABCA4 mutations Phase 1/2 ASTRA study set to begin in the first half of 2025, supported by POLARIS, a pioneering company-sponsored natural history study in Stargardt disease First ever IND clearance for a Protein Splicing gene therapy...
12. Dezember 2024

Gilde Healthcare Portfolio Company Noema Pharma extends Series B financing round

test Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, announced the successful close of a Series B extension financing round with an investment from EQT Life Sciences, bringing the total capital raised in the round to CHF 130 million (approx. USD 147 million). With its investment in Noema Pharma, EQT Life […]

Gilde Healthcare Adcendo Completes $135 Million Series B to Advance First- in-class ADC Pipeline

test Financing led by TCGX, including new investment from TPG, Orbimed Advisors, Venrock Healthcare Capital Partners, Surveyor Capital (a Citadel company), and Logos Capital, with participation from all existing investors Proceeds will be used to support the advancement of multiple first-in-class ADC programs into the clinic and through clinical proof of concept Adcendo, a biotech company […]

Gilde Healthcare portfolio company Levicept Presents Positive Phase II Data for Novel Neurotrophin-3 Inhibitor, LEVI-04 at ACR Convergence 2024

Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis, is presenting the results from its positive Phase II trial of LEVI-04 at the American College of Rheumatology’s annual meeting, ACR Convergence 2024, being held from 14 November to 19 November,...

Gilde Healthcare invests in SynOx Therapeutics and company doses first patients in Phase 3 trial

Gilde Healthcare Leads Series B Extension, Joining Premier Syndicate of Leading Life Science Investors Funding Supports Registrational Phase 3 TANGENT Trial of Emactuzumab, a Best-in-Class CSF-1 Receptor Targeted Antibody, for the Treatment of Tenosynovial Giant Cell Tumour TANGENT Study Underway with First Patients Dosed SynOx Therapeutics Limited...

Gilde Healthcare co-leads in an oversubscribed £80 million Series B financing in Purespring Therapeutics

Funds raised will support Purespring in advancing its AAV pipeline of gene therapy programmes to treat kidney disease, including its lead programme targeting IgA Nephropathy (IgAN) Round brings in new biotech investors, Gilde Healthcare, Sofinnova Partners, Forbion, and British Patient Capital with founding investor Syncona Purespring Therapeutics,...

Gilde Healthcare company Adcendo announces IND clearance by FDA for the phase I/II study of ADCE-D01

ADCE-D01 is a first-in-class antibody-drug conjugate (ADC) targeting uPARAP, an endocytic receptor which is highly overexpressed in mesenchymal cancers including multiple soft tissue sarcoma (STS) subtypes The Phase I/II ADCElerate-01 trial is designed to evaluate the safety, pharmacokinetics, and preliminary efficacy of ADCE-D01 as a monotherapy in...

Gilde Healthcare company Tagworks Pharmaceuticals Appoints Ken Mills as Chief Executive Officer

Biotech industry veteran to lead Tagworks as the company prepares to bring its novel platform and lead antibody-drug (ADC) conjugate program for solid tumors into the clinic in 2025 Founding CEO Marc Robillard, Ph.D., will continue in role of Chief Scientific Officer and as a member of...

Gilde Healthcare company Spire Health merges with Wellinks to form Industry Leader in Predictive Patient Care for Cardiopulmonary Health

Wellinks, the industry leader in virtual-led cardiopulmonary care, announced today it has merged with Spire Health in a non-cash transaction. The transaction merges Spire’s novel patient monitoring technology with Wellinks highly specialized virtual-led cardiopulmonary care model creating a first of its kind fully integrated Predictive Patient Care company....
Loading...
These were all messages
76bcd2f545